Pablo Shimaoka Chagas

Nov 4, 2024 | mdpi.com | Pablo Shimaoka Chagas |Cristiana Bernadelli Garcia |Lucas Sousa |Gabriel da Silva

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jul 23, 2024 | biorxiv.org | Bidhan Bhandari |Sahar Emami Naeini |Pablo Shimaoka Chagas |Hannah Rogers

AbstractIntroduction: Fentanyl and non-pharmaceutical fentanyl use have been the leading causes of opioid-induced death worldwide. Being 50 times stronger than heroin and 100 times stronger than morphine, fentanyl is a potent opioid with overdoses causing over 250,000 deaths since 2018 in the US alone. The treatment of fentanyl addiction is a complex process and a clinical challenge. There is a dire need to find other innovative and alternative modalities in the fight against fentanyl crisis.